Shots:
The US FDA has approved Hovilpri (pritelivir; 100mg, PO) for treating acyclovir, valacyclovir or famciclovir-refractory mucocutaneous herpes simplex virus (HSV) lesions, with or without documented resistance, in immunocompromised adults. Launch is expected by the end of 2026
Approval was supported by the Part C of P-III (PRIOH-1) trial assessing Hovilpri (400mg loading dose on…
